The Bio Report Levine Media Group

Neal Meropol, head of research oncology at Flatiron Health, discusses how real-world evidence can inform better clinical trial designs and accelerate drug development, how Flatiron works with its clients, and a recent study he was involved in that suggest drug developers who want to increase the diversity of clinical trials participants should consider broadening their inclusion criteria.

Hilary Eaton, chief business officer for Profluent, discusses the company’s generative AI engine to produce CRISPR enzymes, its business model, and why its platform has the potential to create other protein therapeutics of varying modalities.

Mike Kelly, CEO of NervGen Pharma, discusses the potential for using therapies designed to allow the nervous system to repair itself, how the company’s lead experimental candidate for spinal cord injury works, and why the same approach holds promise in treating a range of neurodegenerative diseases.

John Dunlop, chief scientific officer of Aliada, discusses its platform technology, its origins at Johnson & Johnson’s Janssen, and the company’s partnering strategy for leveraging the technology.

Sam Murphy, CEO of SalubrisBio, discusses the challenges of pursuing complex diseases with complex therapies, its pipeline, and how its China-based parent has provided it financial freedom from the vagaries of the capital markets.

John Lewis, founder and CEO of Aegis Life, discusses the global need to address infectious diseases, the company’s platform technology, and how it is leveraging that to address the barriers to the delivery of vaccines and antibody therapies in developing economies.